Table 3. Association between the use of statins and polymyalgia rheumatica (PMR).

Characteristics	Cases (%)	Non-cases (%)	ROR Crude (95% CI)	ROR adjusted (95% CI)||	p value¶
	n = 327	n = 1635
Suspected statins	96 (29.4)	47 (2.9)	14.43 (9.89–21.05)	14.21 (9.69–20.85)	<0.001
Sensitivity analysis 1*	n = 327	n = 1635
Suspected or concomitant statins	104 (31.8)	129 (7.9)	5.66 (4.20–7.63)	6.03 (4.40–8.25)	<0.001
Sensitivity analysis 2†	n = 76	n = 848
Suspected statins	18 (23.7)	19 (2.2)	14.15 (6.97–28.75)	14.70 (7.07–30.65)	<0.001
Sensitivity analysis 3‡	n = 307	n = 1535
Suspected statins	88 (28.6)	43 (2.8)	14.22 (7.15–26.92)	14.01 (6.98–24.83)	<0.001
Sensitivity analysis 4§	n = 157	n = 1635
Suspected statins	44 (28.0)	47 (2.9)	14.18 (8.93–22.52)	13.90 (8.65–22.35)	<0.001
Sensitivity analysis 5§	n = 157	n = 1635
Suspected or concomitant statins	46 (29.3)	129 (7.9)	5.55 (3.72–8.29)	5.75 (3.74–8.83)	<0.001

^*cases of PMR were defined as all ADR-reports of PMR.

^†only ADR-reports reported by physicians.

^‡only ADR-reports of patients older than 50 years.

^§cases of PMR were defined as only a report with the preferred term “PMR”.

^||adjusted for age, gender, reporting year, the use of anti-arrhythmic drugs, antihypertensives, anti-depressants, and anti-epileptics.

^¶ p values are for ROR adjusted.